Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by purseon Apr 29, 2015 12:30pm

79 Views

Post# 23676526

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Positive sales trends conitnue

As at Feb. 28, 2015, liquidities, which includes cash and bonds, amounted to $3,965,000, up from $3,178,000 at Nov. 30, 2014. ...........................The company believes that it will be able to adequately finance its operations and meet its cash flow requirements for the next 12 months.

Bullboard Posts

Calibre discovers significant gold in Newfoundland